Patents Examined by Kahsay Habte
-
Patent number: 11976062Abstract: The present invention provides a compound, a salt thereof, or a prodrug thereof as a compound effective for preventing and/or treating fibrosis, the compound being represented by formula (1) (wherein A is an optionally substituted benzene ring; B is optionally substituted aryl or optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom, of Y is a single or double bond when Y is a carbon atom, or of Y is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R1)p is oxo).Type: GrantFiled: December 1, 2022Date of Patent: May 7, 2024Assignees: OSAKA UNIVERSITY, KYOTO UNIVERSITY, INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCESInventors: Ryu Nagata, Yasuo Mori, Masayuki Mori, Motohiro Nishida, Takuro Tomita
-
Patent number: 11976084Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 22, 2021Date of Patent: May 7, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
-
Patent number: 11976056Abstract: The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.Type: GrantFiled: June 19, 2019Date of Patent: May 7, 2024Assignee: UCB PHARMA GMBHInventors: Cecile Pegurier, Laurent Provins, Emre M. Isin, Marie Ledecq
-
Patent number: 11974985Abstract: The present invention relates to a composition of a compound of general formula (A), a pharmaceutically acceptable salt or a prodrug, and a preparation method therefor.Type: GrantFiled: January 30, 2019Date of Patent: May 7, 2024Assignee: HAISCO PHARMACEUTICAL GROUP CO., LTD.Inventors: Yi Mo, Honghu Li, Xing Wan, Fei Ye
-
Patent number: 11970485Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: GrantFiled: October 19, 2022Date of Patent: April 30, 2024Assignee: ELI LILLY AND COMPANYInventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
-
Patent number: 11965099Abstract: An object of the present invention is to provide a dioxazine pigment having excellent fluidity. More specifically, an object of the present invention is to provide a dioxazine pigment in which practically sufficient fluidity is attained in both (1) initial viscosity and (2) storage stability when the dioxazine pigment is used in a printing ink application. The object is attained by providing a dioxazine pigment having a contact angle with respect to water according to an infiltration rate method in a range of 30° to 75°, and a contact angle with respect to 1-bromonaphthalene according to an infiltration rate method in a range of 30° to 75°.Type: GrantFiled: November 2, 2022Date of Patent: April 23, 2024Assignee: DIC CORPORATIONInventors: Shogo Yamada, Hiromasa Kikuchi, Hidehiro Otake
-
Patent number: 11964989Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 20, 2022Date of Patent: April 23, 2024Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
-
Patent number: 11964990Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.Type: GrantFiled: January 19, 2023Date of Patent: April 23, 2024Assignee: AbbVie Inc.Inventors: George A. Doherty, Vikram Bhat, Andrew S. Judd, Andrew J. Souers
-
Patent number: 11964965Abstract: The present disclosure relates to synthesizing and utilizing fluorescent dye compounds or pharmaceutically acceptable salts thereof. Conjugation of amino acid groups to the fluorescent dyes increase specificity and detection of the compound. Methods of manufacture and synthesis of the compounds for use thereof in diagnostic imaging are contemplated.Type: GrantFiled: May 20, 2020Date of Patent: April 23, 2024Assignee: On Target Laboratories, LLCInventors: Sumith A. Kularatne, Pravin Gagare
-
Patent number: 11958840Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.Type: GrantFiled: March 23, 2022Date of Patent: April 16, 2024Assignee: Denali Therapeutics Inc.Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
-
Patent number: 11958828Abstract: An 4,5-bis(4-bromophenyl)-1-hexyl-2-(3-pyridyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: November 7, 2023Date of Patent: April 16, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11958866Abstract: A synthetic protocol to use a thiourea or urea compound and auric chloride as starting materials to obtain thiazole and benzothiazole derivatives. The synthesis can be conducted at room temperature and the final compound can result from cyclization of the thiourea or urea compound in the presence of an Au salt from the auric chloride.Type: GrantFiled: October 17, 2023Date of Patent: April 16, 2024Assignee: KING FAISAL UNIVERSITYInventors: Awal Noor, Ezzat Khan, Umar Ali Khan
-
Patent number: 11958845Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.Type: GrantFiled: September 26, 2022Date of Patent: April 16, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
-
Patent number: 11952371Abstract: A 2-[(1,3-benzoxazol-2-yl)imino]-5,5-diphenylimidazolidin-4-one compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: October 24, 2023Date of Patent: April 9, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Amer A. Amer, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11945810Abstract: The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.Type: GrantFiled: January 2, 2023Date of Patent: April 2, 2024Assignee: Ecstasy LLCInventors: Xiaodong Wang, Baizhi Li
-
Patent number: 11945793Abstract: An 9-(2-hydroxypyridin-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: November 1, 2023Date of Patent: April 2, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11939322Abstract: This invention relates to a method for manufacturing 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, and is industrially preferable, allowing an objective substance to be obtained in high yield more safely and easily than the conventional method.Type: GrantFiled: September 3, 2019Date of Patent: March 26, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroki Serizawa, Akira Kawase, Hiroshi Fukuda, Naoto Hama
-
Patent number: 11939325Abstract: A process of manufacturing biologically active compounds, their analogs, pharmaceutically acceptable salts, solvates, polymorphs, isotopic variants, and intermediates thereof. Notably, the compounds of the formula IA, 1B, 1C. 1D. 1E, 1F and IG for which novel processes have been disclosed, selectively act on the cannabinoid receptors, and with high affinity. The processes for the preparation of the compounds enable the syntheses of cannabinoid modulators on a large-scale that are eco-friendly and economically viable. Additionally, the processes disclosed enable the synthesis of cannabinoid modulators with high purity and in high yield for their use in making drug substance and drug products.Type: GrantFiled: July 26, 2021Date of Patent: March 26, 2024Assignee: MAKScientific, LLCInventors: Alexandros Makriyannis, Kiran Vemuri
-
Patent number: 11939327Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: August 15, 2022Date of Patent: March 26, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
-
Patent number: 11939344Abstract: The specification relates to spirocyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: June 15, 2023Date of Patent: March 26, 2024Assignee: AstraZeneca ABInventor: James Michael Smith